文献速递神经MR

深度学习加速与Wave-CAIPI增强后3D T1-MPRAGE对颅内强化病灶的临床验证

Clinical Validation of Deep Learning-Accelerated versus Wave-CAIPI Postcontrast 3D T1-MPRAGE for Evaluation of Intracranial Enhancing Lesions.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-02-03

前瞻性研究纳入115例门诊增强脑MRI患者,比较DL加速与Wave-CAIPI加速的增强后3D T1-MPRAGE序列。由两名神经放射科医生盲法随机头对头评估。结果显示DL-T1-MPRAGE在强化病灶显示、噪声、伪影、锐利度及整体诊断质量方面均非劣于Wave-CAIPI序列。

要点

  • DL-T1-MPRAGE与Wave-CAIPI T1-MPRAGE采集时间均为2分11秒,R=2×2,可在不延长时间下改善图像质量。
  • 对脑实质、硬脑膜、软脑膜及室管膜强化病灶显示均非劣于Wave-CAIPI序列。
  • 小型微小强化病灶在DL序列上显示效果与Wave-CAIPI相当,可用于日常增强报告。

核心结论

  • 高加速的增强后DL-T1-MPRAGE图像质量非劣于临床已验证的Wave-CAIPI T1-MPRAGE加速序列。
  • DL-T1-MPRAGE对微小强化病灶的显示有所提升。

研究设计与样本

  • 前瞻性研究,经机构审查委员会批准,门诊患者行3T MRI增强脑扫描。
  • 共纳入115例患者,女68例/男47例,平均年龄54±10岁;排名前三临床指征为肿瘤52%、血管病变24%、头痛8%。
  • 每个受试者均采集Wave-CAIPI增强后T1-MPRAGE(R=2×2,采集时间2分11秒)及研究用DL-T1-MPRAGE(R=2×2,采集时间2分11秒)。
  • DL重建分两步:第一步基于变分网络进行6次数据一致性更新与神经网络评估迭代,第二步采用超分辨率算法进一步图像增强。
  • 两名独立神经放射科医生采用已发表量表盲法随机头对头比较两条序列;第三名委员会认证神经放射科医生对评分不一致的病例进行裁定。

关键影像表现/征象

  • DL-T1-MPRAGE显示强化病灶优于或不劣于Wave-CAIPI序列,全部强化病理病例中两名阅片者意见一致。
  • DL-T1-MPRAGE对小型微小脑实质、硬脑膜及软脑膜强化病灶显示效果相当。
  • 评估量表涵盖硬脑膜、脑实质、软脑膜及室管膜强化显示、锐利度、噪声、伪影和整体诊断质量。

诊断标准与关键数值

  • 非劣效性检验采用15%界值。

临床应用与阅片要点

  • DL-T1-MPRAGE可作为3T增强后容积T1序列的可行替代,用于显示各类颅内强化病变。
  • 该序列可能改善微小强化病灶的可视化,有助于早期发现软脑膜及硬脑膜病变。
  • 不增加采集时间,适合门诊增强脑MRI流程整合。

局限性

  • 研究采用单一影像对比验证,未报告与病理金标准的诊断准确性指标。
  • 原文未报道病灶数量、大小分布及病灶类型亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Deep learning (DL) reconstruction methods have shown promise in accelerating 2D MRI sequences but have yet to be extensively validated for routine 3D volumetric MRI applications. Our purpose was to assess the diagnostic quality of a novel DL-accelerated 3D T1-MPRAGE compared with a state-of-the-art wave-controlled aliasing in parallel imaging (Wave-CAIPI) accelerated 3D T1-MPRAGE for evaluating intracranial enhancing lesions.

MATERIALS AND METHODS: This prospective study was approved by the Institutional Review Board. Patients undergoing contrast-enhanced brain MRI in an outpatient setting were scanned on 3T MRI systems. The imaging protocol included a state-of-the-art Wave-CAIPI postcontrast T1-MPRAGE (acceleration factor [R] = 2 × 2, acquisition time [TA] = 2:11 minutes) and a research-based postcontrast DL-T1-MPRAGE (R = 2 × 2, TA = 2:11 minutes). The DL-based reconstruction process involved 2 steps. The first step, inspired by variational networks, involved 6 iterations alternating between data consistency updates and neural network evaluation. The second step applied a super-resolution algorithm for further image enhancement. Two independent neuroradiologists conducted a blinded, randomized head-to-head comparison of the 2 sequences by using a previously published scale across the following criteria: visualization of dural, parenchymal, leptomeningeal, and ependymal enhancement; sharpness; noise; artifacts; and overall diagnostic quality. A third board-certified neuroradiologist adjudicated cases with discrepant ratings. Noninferiority of DL-T1-MPRAGE was tested by using a 15% margin.

RESULTS: A total of 115 patients (68 women/47 men, mean age = 54 ± 10 years) were included. The top 3 clinical indications were: neoplasm (52%), vascular lesions (24%), and headache (8%). DL-T1-MPRAGE was noninferior to Wave-CAIPI T1-MPRAGE for delineating enhancing lesions with unanimous agreement in all cases with enhancing pathology. It was also noninferior in terms of noise perception (P < .0001), artifact (P < .0001), sharpness (P = .001), and overall diagnostic quality (P < .0001). DL-T1-MPRAGE provided equivalent visualization of small, subtle enhancing parenchymal, dural, and leptomeningeal lesions.

CONCLUSIONS: The highly accelerated postcontrast DL-T1-MPRAGE demonstrated noninferior image quality compared with the clinically validated Wave-CAIPI T1-MPRAGE accelerated sequence while offering enhanced visualization of subtle enhancing lesions.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Tabari, Vejdani-Jahromi, Lang, et al. Clinical Validation of Deep Learning-Accelerated versus Wave-CAIPI Postcontrast 3D T1-MPRAGE for Evaluation of Intracranial Enhancing Lesions. AJNR Am J Neuroradiol. 2026. PMID: 41617400. doi:10.3174/ajnr.A8992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。